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ABSTRACT 
An ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method has been developed for the 
determination of gliclazide in human plasma using gliclazide-d4 as the internal standard (IS). The plasma samples were prepared by 
protein precipitation with acetonitrile employing 50 µL human plasma. Chromatography was performed on Acquity UPLC BEH C18 
(50 mm × 2.1 mm, 1.7 µm) analytical column under isocratic conditions using a mobile phase which consisted of 0.1% formic acid in 
water-acetonitrile (10:90, v/v). The MRM transitions for gliclazide (m/z 324.2 → 127.3) and gliclazide-d4 (m/z 328.2 → 127.4) were 
monitored on a triple quadrupole mass spectrometer, operating in the positive ionization mode. The method was validated over a 
dynamic concentration range of 1.0-2000 ng/mL for gliclazide. Matrix effect was assessed by post-column analyte infusion and the 
mean extraction recovery was 95.7 % across six quality control levels. Stability of gliclazide in plasma was evaluated under different 
conditions like bench top, auto sampler, dry and wet extract, freeze-thaw and long term stability. The method was applied to a 
bioequivalence study with 30 mg gliclazide tablet formulation in 28 healthy subjects under fasting. Further, the assay reproducibility was 
confirmed by reanalysis of 129 incurred samples.  
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INTRODUCTION
Diabetes mellitus is a metabolic disorder characterized by 
disrupted insulin production, leading to increase in blood glucose 
level and other complications such as neuropathy, cardiopathy and 
renal dysfunction [1-3]. It is classified as type 1 or type 2 diabetes 
based on different stages of the disease. Type 1 diabetes is 
ascribed to an early-onset autoimmune disease marked by the 
destruction of β-cells of the pancreas, which results in a partial or 
complete lack of insulin production and the inability of the body to 
control glucose homeostasis [3].  Type 2, a non-insulin dependent 
diabetes is a complex metabolic disorder which occurs at a later 
stage and is most common in the overweight population [4].  It is 
caused by genetic and environmental factors, as evident from a 
study correlating the loss of function gene variants in GPR120 
with increased risk of type 2 complications [5, 6]. Gliclazide is a 
potent type 2 second generation antidiabetic drug used to enhance 
insulin secretion, and possesses beneficial extra pancreatic effects 
that makes it potentially useful in type 1 as well [7]. Gliclazide is 
completely absorbed from the gastro-intestinal tract with mean 
absolute bioavailability of 97 % and is highly protein bound. After 
oral administration the peak plasma concentration is achieved in 
about 6 h and is more than 90 % recovered unchanged in plasma. 
Although six main metabolites are identified in urine, no active 
metabolites are found in plasma [8].  
Either monotherapy or combination therapy is required for 
maintaining long term glycemic control with oral antidiabetic 
agents. Further, it is essential to monitor their plasma 
concentration for effective control of blood glucose levels and for 
therapeutic drug monitoring to optimize dose strength and dosing 
regimen. Thus, development of adequately sensitive, selective and 
rapid method is required to determine these agents in plasma. 
Several methods are reported to determine gliclazide, either as a 
single analyte [9-14] or in combination with other antidiabetic 
agents [15-21] in human serum or plasma. These methods have 
employed high performance liquid chromatography with UV [9, 
11, 14, 17, 19], electrochemical [12] or mass detection [10, 13, 15, 
16, 18, 20, 21] for estimation of gliclazide. However, there are no 
reports on the use of UPLC-MS/MS for the quantification of 
gliclazide in human plasma. Thus, in the present study a selective, 
sensitive and rapid UPLC-MS/MS method has been developed 
and validated for accurate determination of gliclazide in human 
plasma for routine therapeutic drug monitoring. The method 
employs 50 µL plasma sample and a chromatographic analysis 
time of 1.2 min. The effect of endogenous matrix components on 
the quantification of gliclazide and its stability in plasma is 
extensively studied. Further, the utility of the method is 
demonstrated by a bioequivalence study in healthy subjects.  
 
EXPERIMENTAL 
Chemicals and materials 
Reference standards of gliclazide (99.25 %) and 
gliclazide-d4 (99.58 %) were procured from Clearsynth Labs Pvt. 
Ltd. (Mumbai, India). HPLC grade acetonitrile and methanol were 
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procured from Mallinckrodt Baker, S.A.de C.V. (Estado de 
Mexico, Mexico). Formic acid (90%) was obtained from S.D. 
Fine Chemicals Ltd. (Mumbai, India). Water used in the entire 
analysis was prepared from Milli-Q water purification system 
from Millipore (Bangalore, India). Blank human plasma was 
obtained from Supratech Micropath (Ahmedabad, India) and was 
stored at –20 °C until use. 
Liquid Chromatographic and Mass Spectrometric Conditions  
An Acquity UPLC system from Waters Corporation 
(Milford, MA, USA) consisting of binary solvent manager, 
sample manager and column manager and linked to a triple 
quadrupole Quattro Premier XE mass spectrometer with an 
electrospray ionization source (Milford, MA, USA) was used in 
the study. The analysis of gliclazide and IS was performed on a 
Waters Acquity UPLC BEH C18 (50 mm × 2.1 mm, 1.7 µm) 
analytical column, maintained at 25 °C in a column oven. The 
mobile phase consisted of 0.1% formic acid in water - acetonitrile 
(10:90, v/v). The flow rate of the mobile phase was kept at 0.300 
mL/min. The sample manager temperature was maintained at 5°C 
and the pressure of the system was 6200 psi. Ionization and 
detection of gliclazide and IS was carried out on a triple 
quadrupole mass spectrometer in the positive ionization mode. 
The source dependent parameters set for the analyte and IS were, 
cone gas flow: 120 L/h; desolvation gas flow: 640 L/h; capillary 
voltage: 1.4 kV, source temperature: 120°C; desolvation 
temperature: 400°C; extractor voltage: 4.0V. The pressure of 
argon used as collision activation dissociation gas was 0.120 Pa. 
The optimum value for cone voltage and collision energy was kept 
at 25 V and 31 eV for gliclazide and 24 V and 32 eV for IS 
respectively. Quadrupole 1 and 3 were maintained at unit mass 
resolution and the dwell time was set at 100 ms.  Mass Lynx 
software version 4.1 was used to control all parameters of UPLC 
and MS. 
Standard stock, calibration standards and quality control 
samples  
The standard stock solution of gliclazide (500 µg/mL) was 
prepared by dissolving requisite amount in methanol. Further, an 
intermediate solution (100 µg/mL and 50.0 µg/mL) for spiking 
was prepared in methanol:water (50:50, v/v). Calibration 
standards and quality control (QC) samples were prepared by 
spiking blank plasma with the intermediate solutions. Calibration 
curve standards for gliclazide were prepared at 1.00, 2.00, 5.00, 
15.0, 45.0, 100, 250, 500, 1000, 2000 ng/mL concentrations, while 
quality control samples were prepared at six levels, 1600 ng/mL 
(HQC, high quality control), 1200/800 ng/mL (MQC-1/2, medium 
quality control), 400/3.00 ng/mL (LQC-1/2, low quality control) 
and 1.00 ng/mL (LLOQ QC, lower limit of quantification quality 
control). Stock solution (100 µg/mL) of the internal standard was 
prepared by dissolving 1.0 mg of gliclazide-d4 in 10.0 mL of 
methanol. Its working solution (2.50 µg/mL) was prepared by 
appropriate dilution of the stock solution in methanol:water 
(50:50, v/v). All standard stock and working solutions used for 
spiking were stored at 5 °C, while CSs and QC samples in plasma 
were kept at -70 °C until use.  
Protocol for sample preparation 
Prior to analysis, all frozen subject samples, calibration 
standards and quality control samples were thawed and allowed to 
equilibrate at room temperature. To an aliquot of 50 µL of spiked 
plasma sample/subject sample, 25 µL of internal standard was 
added and vortexed for 10s. Further, 600 µL of acetonitrile was 
added and vortexed for another 60 s. The samples were then 
centrifuged at 13148 × g for 10 min at 10°C. The supernatant layer 
was separated and evaporated to dryness in a thermostatically 
controlled water-bath maintained at 40 °C under a gentle stream of 
nitrogen for 10 min. After drying, the residue was reconstituted 
with 250 µL of mobile phase solution. The solution was briefly 
vortexed for 15s and 10 µL was used for injection in the 
chromatographic system. 
Method validation procedures 
Validation of the method for the estimation of gliclazide 
was carried out as per the USFDA guidelines [22]. System 
suitability experiment was performed by injecting six consecutive 
injections using aqueous standard mixture of analyte (1200 
ng/mL) and IS (2.50 µg/mL) at the start of each batch. System 
performance was studied by injecting one extracted blank 
(without analyte and IS) and one extracted LLOQ sample with IS 
at the beginning of each analytical batch and before re-injecting 
any sample during method validation. The carryover effect of the 
auto-sampler was evaluated by sequentially injecting extracted 
blank plasma  ULOQ sample  extracted blank plasma  
LLOQ sample extracted blank plasma at the beginning of each 
batch. The selectivity of the method towards endogenous plasma 
matrix components was assessed in eight batches (5 normal of 
K3EDTA plasma, 1 heparinized, 1 haemolysed and 1 lipemic) of 
blank human plasma. The selectivity of the method towards 
commonly used medications in human volunteers was done for 
paracetamol, chlorpheniramine maleate, diclofenac, caffeine, 
acetylsalicylic acid and ibuprofen in six different batches of 
plasma having K3-EDTA as anticoagulant. Their stock solutions 
(100 µg/mL) were prepared by dissolving requisite amount in 
methanol. Further, working solutions (1.0 µg/mL) were prepared 
in the mobile phase and 10 µL was injected to check for any 
possible interference at the retention time of analyte and IS. The 
cross talk of MRM for analyte and IS was checked using highest 
standard on calibration curve and working solution of IS.    
The linearity of the method was ascertained through six 
calibration curves containing ten non-zero concentrations. The 
area ratio response (analyte/IS) obtained from multiple reaction 
monitoring was used for regression analysis. Each calibration 
curve was analyzed individually by using least square weighted 
(1/x2) linear regression. A correlation coefficient (r2) value >0.99 
was desirable for all the calibration curves. Reinjection 
reproducibility for extracted samples was also checked by 
analyzing one entire analytical batch, stored at 5 °C.   
Intra-batch accuracy and precision was checked through 
replicate analysis of plasma samples on a single batch. The run 
consisted of a calibration curve and six replicates of LLOQ, 
LQC-2, LQC-1, MQC-2, MQC-1 and HQC samples. The 
inter-batch accuracy and precision were assessed by analysis of 
six batches at six QC levels on three consecutive validation days.  
Ion suppression/enhancement effects on the MRM 
LC-MS/MS sensitivity were evaluated by post column analyte 
infusion experiment. A standard solution containing gliclazide 
(1200 ng/mL) and IS was infused post column into the mobile 
phase at 10 µL/min employing infusion pump. Aliquots of 10 µL 
of extracted control plasma were then injected into the column and 
MRM chromatograms were acquired for the analyte and IS.    
The extraction recovery and matrix effect were assessed as 
recommended by Matuszewski et al. [23]. Both the parameters 
were evaluated at HQC, MQC-1/2 and LQC-1/2 and LLOQ levels 
in six replicates. Extraction recovery (RE) was calculated by 
comparing the mean area response of extracted samples (spiked 
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before extraction) with unextracted samples (spiked after 
extraction) at each QC level. The recovery of IS was similarly 
estimated. Matrix effect, expressed as matrix factors (MFs), was 
assessed by comparing the mean area response of post-extraction 
fortified  samples with mean area of solutions prepared in mobile 
phase solutions (neat standards). IS-normalized MFs 
(gliclazide/IS) were calculated to access the variability of the 
assay due to matrix effects. Relative matrix effect was assessed 
from the precision (% CV) values of the slopes of the calibration 
curves prepared from eight different plasma lots/sources.  
All stability results were evaluated by measuring the area 
response (analyte/IS) of stability samples against freshly prepared 
comparison standards. Stock solutions of gliclazide and IS were 
checked for short term stability at room temperature and long term 
stability at 5 °C. The solutions were considered stable if the 
deviation from nominal value was within ±10.0 %. Bench top (at 
room temperature), dry extract, wet extract and freeze-thaw 
stability (at -20 °C and -70 °C) were performed at LQC-2 and 
HQC levels using six replicates. Long term stability of spiked 
plasma samples stored at -20 °C and -70 °C was also studied at 
both these levels. The samples were considered stable if the 
deviation from the mean calculated concentration of freshly 
thawed quality control samples was within ±15.0 %.  
Method ruggedness was studied with two precision and 
accuracy batches. The first batch was analyzed on two different 
columns (same make but different batch no.), while the second 
batch was analyzed by two different analysts. Dilution integrity 
experiment was conducted by diluting the stock solution prepared 
as spiked standard at concentration of 4000 (2 times of ULOQ) 
ng/mL for gliclazide. The precision and accuracy for dilution 
integrity standards at 1/5 (800.0 ng/mL) and 1/10th (400.0 ng/mL) 
dilutions for the analyte were determined by analyzing the 
samples against freshly prepared calibration curve standards.  
Bioequivalence study and incurred sample results 
The bioequivalence study was conducted with a single 
dose of a modified release tablets (30 mg gliclazide, Valpharma 
International S.p.A., Italy) and DIAMICRON® modified release 
tablet  (30 mg of gliclazide, Les Laboratories Servier, France) 
formulations to 28 normal, healthy, adult subjects under fasting. 
Each subject was judged to be in good health through medical 
history, physical examination and routine laboratory tests. Written 
consent was taken from all the subjects after informing them about 
the objectives and possible risks involved in the study. The study 
was conducted as per the International Conference on 
Harmonization, E6 Good Clinical Practice guidelines [24]. Blood 
samples were collected at 0.00 (pre-dose), 0.50, 1.00, 1.50,  2.00, 
2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 5.50, 6.00, 6.50, 7.00, 7.50, 8.00, 
9.00, 10.0, 11.0, 12.0, 14.0, 16.0, 24.0, 48.0, 72.0, 96.0 and 120 h 
after oral administration of the dose for test and reference 
formulation. Plasma was separated by centrifugation and kept 
frozen at -20°C till the completion of period and then at -70°C 
until analysis. During study, subjects had a standard diet while 
water intake was unmonitored. The pharmacokinetic parameters 
of gliclazide were estimated by non-compartmental model using 
WinNonlin software version 5.2.1 (Pharsight Corporation, 
Sunnyvale, CA, USA). 
 An incurred sample reanalysis was also carried out by 
reanalysis of 129 subject samples. The selection criterion was 
based on samples which were near the Cmax and the elimination 
phase in the pharmacokinetic profile of the drug. The results 
obtained were compared with the initial results. The percent 
change in the value should not be more than ±20% [25]. 
 
RESULTS AND DISCUSSION  
I. UPLC-MS/MS method optimization 
In the present work electrospray ionization (ESI) source was used 
to maximize sensitivity and obtain good linearity in the regression 
curves. During ionization in the positive ionization mode, 
gliclazide and IS formed predominantly protonated precursor ions 
in the full scan Q1 mass spectra at m/z 324.2 and 328.2 
respectively. The most abundant product ions in Q3 mass spectra 
were found at m/z 127.3 and 127.4 for gliclazide and its deuterated 
analog as IS but applying optimum collision energy of 31 and 32 
eV respectively (Figure 1). This product ion can be attributed to 
the substructure containing hexahydro-cyclopenta[c]pyrrole 
moiety. In addition to the quantification transition, a qualifying 
transition was also monitored for the identification of gliclazide 
(m/z 324.2 → 110.2) and IS (m/z 328.2 → 110.4). A dwell time of 
100 ms was adequate to have sufficient no. of data points for 
quantification.  
 
Figure 1 Product ion mass spectra of (A) gliclazide (m/z  324.2 → 
127.3, scan range 40-400 amu) and (B) internal standard, 
gliclazide-d4 (m/z 328.2 → 127.4, scan range 40-400 amu) in the 
positive ionization mode. 
Reported methods have used several reversed-phase columns like 
Techsphere C8 [9], Hypersil BDS C18 [10, 15], Cepcell Pak C18 
[11], Apollo C18 [12], Diamonsil C18 [13] with different 
dimensions for chromatographic separation of gliclazide. 
Foroutan et al. [14] have used a monolithic column for the 
analysis of gliclazide from human plasma. In the present work, the 
chromatographic analysis of gliclazide was suitably optimized on 
UPLC BEH C18 (50 mm × 2.1 mm, 1.7 µm) column using various 
combinations of acetonitrile/methanol with acidic buffers (formic 
acid-ammonium formate and acetic acid-ammonium acetate) and 
acidic modifiers like formic acid and acetic acid in different 
concentrations. The aim was to have adequate retention, response 
and peak shape with a short run time. Although adequate retention 
was obtained under all mobile phase conditions, the peak shape 
was not acceptable when the aqueous part was greater than 25 % 
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with longer retention time. Further, the response was much higher 
in formic acid compared to both the acidic buffers. Thus, a mobile 
phase consisting of 0.1% formic acid in water - acetonitrile (10:90, 
v/v) was found best in terms of sensitivity, peak shape and short 
analysis time.  
 
Figure 2 Representative MRM ion-chromatograms of (A) double 
blank plasma without gliclazide and gliclazide-d4, (B) blank 
plasma with working solution of gliclazide-d4 (m/z 328.2 →  
 
127.4), (C) gliclazide (m/z 324.2 → 127.3) at 1.0 ng/mL 
concentration of gliclazide and gliclazide-d4 (D) real subject 
sample at Cmax and gliclazide-d4 after administration of 30 mg 
gliclazide. 
The entire chromatographic run was completed within 1.2 min. 
All previous methods [9-16] have used general internal standards 
(ISs) for the analysis of gliclazide. However, according to the 
FDA guidelines [22] a stable and labeled compound should be 
preferred which has more structural similarity compared to 
general standards. Gliclazide-d4, used in this work gave excellent 
results with acceptable accuracy and precision at each QC level. 
The MRM chromatograms illustrated in Figure 2 of extracted 
blank plasma (double blank), blank plasma fortified with IS, 
gliclazide (at 1.0 ng/mL) and IS and a subject sample at Cmax 
demonstrates the overall performance and selectivity of the 
method. Results of post-column infusion experiment in Figure 3 
indicate no ion suppression or enhancement at the retention time 
of gliclazide and IS. 
Reported methods have used either protein precipitation (PP) [12, 
14-16] or liquid-liquid extraction (LLE) [9, 11, 13] for sample 
preparation of gliclazide from plasma or serum samples. 
However, to keep the extraction protocol simple and quick with 
minimum steps, PP was tried with different protein precipitants 
like acetonitrile, methanol, ethanol and acetone. The extraction 
efficiency obtained in these solvents was quantitative (≥ 81 %), 
but minimum interference of endogenous components was found 
in presence of acetonitrile. At the same time the peak shape and 
analyte response was much higher and consistent at all QC levels 
with acetonitrile and hence was selected in the present work. The 
salient features of the present work in comparison with reported 
methods are presented in Table 1. 
 
 
Figure 3 Injection of extracted blank human plasma during post 
column infusion of (A) gliclazide at 2000 ng/mL and (B) 
gliclazide-d4. 
 
Table 1 Comparison of salient features of chromatographic methods developed for gliclazide in biological matrices 
aAlongwith metformin; bAlong with benazepril and valsartan; LLE: liquid-liquid extraction; PP: protein precipitation; ACN: 
acetonitrile; DCM: dichloromethane 
Sr. 
No. 
Technique Sample volume  
( µL); extraction 
procedure; internal 
standard 
Linear range  
(ng/mL); retention time 
/run time (min) 
Application Ref. 
1 HPLC-UV  
(230 nm) 
  
100 (serum); LLE 
with toluene; 
phenytoin 
75-10,000; 6.8/8.0  Pharmacokinetic study  with 
80 mg gliclazide in 12 healthy 
volunteers  
9 
2 LC-MS/MS 1000 (plasma); 
Non-porous 
membrane probe; 
tolbutamide 
100-9850; 2.71/3.00  Pharmacokinetic study  with 
80 mg gliclazide in 1 healthy 
volunteer 
10 
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Results for method validation  
The calibration curves were linear over the concentration range of 
1.0-2000 ng/mL with correlation coefficient (r2) ≥ 0.9995 for 
gliclazide. The mean equation for five calibration curves was y = 
(0.00081 ± 0.00001) x - (0.000041 ± 0.000034). The standard 
deviation value for slope, intercept and correlation coefficient 
observed were 0.00001, 0.000034 and 0.0001 respectively. The 
accuracy and precision (%CV) observed for the calibration curve 
standards ranged from 97.6 to 101.6 % and 0.88 to 2.92 % 
respectively. The lowest concentration (1.00 ng/mL) in the 
standard curve was measured at a signal-to-noise ratio (S/N) of ≥ 
10.0.  
The intra-batch and inter-batch precision and accuracy results 
obtained at each QC level are shown in Table 2. The intra-batch 
precision (%CV) ranged from 1.04 to 2.89 % and the accuracy 
was within 99.6 to 100.7 %.  For the inter-batch experiments, the 
precision varied from 1.09 to 2.95 % and the accuracy ranged 
from 98.6 to 100.4 %. 
 
 
Table 2 Intra-batch and inter-batch precision and accuracy for gliclazide 
 
 
Nominal 
concentration 
(ng/mL) 
Intra-batch (n = 6; single batch) Inter-batch (n = 30; 6 from each batch) 
Mean conc. 
found  
(ng/mL) 
% CV % Accuracy Mean conc. 
found  
(ng/mL) 
% CV % Accuracy 
HQC (1600) 1604.2 2.07 100.2 1591.0 2.23 99.4 
MQC-1 (1200) 1195.0  1.04 100.3 1204.6 1.09 99.6 
MQC-2 (800.0) 802.44 2.41 99.6 797.24 2.95 100.4 
LQC-1 (400.0) 402.48 2.37 100.6 398.14 1.92 99.5 
LQC-2 (3.00) 3.018 2.89 100.6 2.987 2.62 99.5 
LLOQ QC (1.000) 1.007 2.81 100.7 0.986 2.91 98.6 
                   CV: coefficient of variation; HQC: high quality control; MQC: medium quality control; 
                   LQC: low quality control; LLOQ QC: lower limit of quantitation quality control 
 
The extraction recovery and matrix effect results for gliclazide and IS at different QC levels are presented in Table 3. The mean recovery 
across QC levels for gliclazide and IS ranged from 94.6 to 96.7 %, while the matrix effect expressed matrix factors varied from 0.983 to 
1.014. 
Table 3 Extraction recovery and matrix factor for gliclazide at different QC levels. 
3 Semi-micro 
HPLC-UV  
(229 nm) 
100 (plasma); LLE 
with chloroform; 
glyburide 
100-10,000; 4.1/8.0 
 
Bioequivalence study with two 
formulations in 20 healthy 
subjects  
11 
4  HPLC-electroche
mical detection 
100 (plasma); PP with 
ACN; 
methyl-4-hydroxy 
benzoate 
16-1300; 5.0/20.0  Pharmacokinetic study  with 
80 mg gliclazide in 1 healthy 
volunteer 
12 
5  LC-MS/MS 200 (plasma); LLE 
with n-hexane and 
DCM; tolbutamide 
2.5-2000; 3.55/5.0 Pharmacokinetic study  with 
30 mg gliclazide in 20 patients 
13 
6  HPLC-UV  
(230 nm) 
450 (plasma); PP with 
ACN; glibenclamide 
10-5000; 3.2/6.0 Pharmacokinetic study  with 
80 mg gliclazide in 12 healthy 
volunteer 
14 
7a LC-MS/MS 200  (plasma); PP 
with ACN; huperzine 
10-10000; 1.47/2.0 Bioequivalence study with 40 
mg gliclazide in 20 healthy 
subjects 
15 
8b LC-MS/MS 100  (plasma); PP 
with methanol; 
ketaconazole 
20-2000;  6.5/8.0 Protein binding interaction 
with Rhein 
16 
 
9 UPLC-MS/MS 50 (plasma);  PP with 
ACN; gliclazide-d4 
1.0-2000; 0.94/1.20 Bioequivalence study with 30 
mg gliclazide in 28 healthy 
subjects 
PW 
 
QC conc. 
(ng/mL) 
Mean area response (n = 6) Extraction 
recovery, % 
(B/A) 
Matrix factor 
A B C Analyte 
(A/C) 
IS     
IS-normalized 
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               a values for gliclazide-d4;  
    A: mean area response of six replicates prepared by spiking in extracted blank plasma;  
    B: mean area response of six replicates prepared by spiking before extraction;  
    C: mean area response of six replicates prepared by spiking in mobile phase (neat samples)  
IS: Internal standard; LQC: low quality control; MQC: medium quality control; HQC: high quality control. 
 
Further, another essential criteria to evaluate matrix effect, 
expressed as relative matrix in different plasma lots/batches 
showed % CV values in the measurement of slope of standard 
curves was 2.84 (Table 4). 
Table 4 Relative matrix effect in eight different lots of human 
plasma for gliclazide 
Plasma lot Slope 
Lot-1 0.000803 
Lot-2 0.000792 
Lot-3 0.000821 
Lot-4 0.000845 
Lot-5 0.000788 
Lot-6 (heparinized) 0.000817 
Lot-7 (haemolysed) 0.000832 
Lot-8 (lipemic) 0.000778 
Mean 0.000810 
±SD 0.000023 
%CV 2.84 
    SD: standard deviation; CV: coefficient of variation 
 
The stock solutions for short term stability of gliclazide and IS 
were stable at room temperature up to 27 h and between 2-8 °C for 
a minimum period of 24 days. Gliclazide in control human plasma 
(bench top) at room temperature was stable for at least 20 h at 
25°C and for minimum of five freeze and thaw cycles. Dry and 
wet extract stability of the spiked quality control samples was 
determined up to 24 h and 48 h respectively. Long term stability of 
the spiked quality control samples was remained unaffected up to 
186 days. The detailed stability results at LQC and HQC levels in 
plasma are presented in Table 5.  
For method ruggedness, the precision (%CV) and accuracy values 
for two different columns ranged from 2.13 to 4.45 % and 97.6 to 
104.6 % respectively across five quality control levels. For the 
experiment with different analysts, the results for precision and 
accuracy were within 1.29 to 2.05 % and 95.1 to 102.4 % 
respectively at these levels. The dilution integrity experiment was 
performed with an aim to validate the dilution test to be carried out 
on higher analyte concentration above the upper limit of 
quantification (ULOQ), which may be encountered during real 
subject sample analysis. The precision and accuracy values for 1/2 
and 1/10th dilution ranged from 2.95-3.46 % and 97.8-105.4 % for 
gliclazide.
 
Table 5 Stability results of gliclazide in plasma under various conditions (n = 6) 
Storage conditions Nominal 
concentration 
(ng/mL) 
Mean stability 
sample 
(ng/mL) ± SD 
Change (%) 
Bench top stability at 25 °C, 20 h 1600 1604.4 ± 39.8 0.28 
3.00 2.99 ± 0.07 -0.19 
Freeze & thaw stability at -20 °C 1600 1606.0 ± 35.8 0.38 
3.00 3.019 ± 0.06 0.65 
Freeze & thaw stability at -70 °C 1600 1594.0 ± 36.0 -0.38 
3.00 2.99 ± 0.07 -0.22 
Dry extract stability at  2-8°C, 24 h 1600 1598.6 ± 35.7 -0.09 
3.00 3.02 ± 0.07 0.51 
Wet extract stability at 2-8°C, 48 h 1600 1608.2 ± 31.5 0.51 
3.00 2.98 ± 0.06 -0.63 
Long term stability at -20 °C, 186 days 1600 1609.4 ± 30.5 0.59 
3.00 3.01 ± 0.08 0.33 
Long term stability  at  -70 °C, 186 days 1600 1607.4 ± 19.8 0.46 
3.00 2.98 ± 0.06 -0.34 
                       SD: standard deviation; n: number of replicates 
3.00 7292 6935 6718 95.1 (96.3)a 1.085 1.070    1.014 
400.0 974865 935241 904587 95.9 (95.9)a 1.077 1.083    0.994 
800.0 1985678 1878746 1848514 94.6 (96.7)a 1.074 1.062    1.011 
1200 2928627 2816242 2737784 96.2 (95.1)a 1.069 1.079    0.990 
1600 3895563 3762278 3688412 96.6 (94.7)a 1.056 1.074    0.983 
 J. of Modern Drug Discovery And Drug Delivery Research           Volume 2 / Issue 1                                ISSN: 2348 –3776 7 
100
samples comparisonMean 
samples comparisonMean –  samplesstability Mean  (%)  Change* ×=  
 
 
Application of the method in healthy human subjects and 
incurred sample results 
The validated method was successfully applied for the assay of 
gliclazide in healthy Indian subjects. Figure 4 shows the plasma 
concentration vs. time profile of gliclazide in healthy subjects 
under fasting.  
 
Figure 4 Mean plasma concentration-time profile of gliclazide 
after oral administration of 30 mg of test (modified release tablet, 
Valpharma International, Italy) and reference (DIAMICRON® 
tablet, Les Laboratories Servier, France) formulation to 28 healthy 
subjects. 
It was possible to analyze about 2500 samples (subject 
samples, calibration and QC samples) during a period of 8 days 
and the results obtained were well within the acceptable limits. 
The main pharmacokinetic parameters of gliclazide, Cmax, AUC0-t, 
AUC0-inf, Tmax, Kel and t1/2 for both the formulations are shown in 
Table 6. The Cmax, Tmax, Kel and t1/2 values obtained were in good 
agreement with a previous report with 30 mg gliclazide modified 
release tablets in Chinese subjects [13]. Further, there was no 
apparent statistical difference between the two formulations in any 
parameter. The ratios of mean log-transformed parameters (Cmax, 
AUC0-120, and AUC0-inf) and their 90% CIs were all within the 
defined bioequivalence range of 80-125 %. These observations 
confirm the bioequivalence of the test formulation with the 
reference product in terms of rate and extent of absorption. 
 
Table 6 Mean pharmacokinetic parameters, comparison of treatment ratios of 90% CIs of natural log (Ln)-transformed parameters 
following oral administration of 30 mg gliclazide tablet formulation in 28 healthy Indian subjects under fasting. 
 
Parameter  Test  
(Mean ±SD) 
Reference  
(Mean ±SD) 
Ratio (test/ 
reference), 
% 
90% CI 
(Lower – 
Upper) 
Power Intra subject 
variation,  
% CV 
Cmax  
(ng/mL) 
1465.52  ± 190.25 1472.31 ± 205.36 99.5 95.3-104.1 0.9995 4.65 
 
AUC0-120 h 
(h. ng/mL) 
 
11245.2  ± 2045.5 
 
12045.6 ± 2060.9 
 
99.3 
 
93.1-105.7 
 
0.9997 
 
5.25 
AUC0-inf 
(h. ng/mL) 
 
11965.4  ± 2102.6 
 
12445.0 ± 2132.6 
 
96.1 
 
92.7-99.5 
 
0.9998 
 
4.92 
 
Tmax (h) 
 
5.05  ± 1.25 
 
5.26  ± 1.35 
 
-- 
 
-- 
 
-- 
 
-- 
 
t1/2 (h) 
 
9.19  ± 1.24 
 
9.46 ± 1.02 
 
-- 
 
-- 
 
-- 
 
-- 
 
Kel (1/h) 
 
0.075  ± 0.006 
 
0.073 ± 0.005 
 
-- 
 
-- 
 
-- 
 
-- 
 
The incurred sample reanalysis (ISR) results are represented in Fig. 5. The % change for assay reproducibility in 129 incurred samples 
was within ±16 % for gliclazide. This authenticates the reproducibility of the proposed method. 
 
Figure 5 Graphical representation of % change in concentration 
during reanalysis of 129 incurred samples for gliclazide. 
 
CONCLUSIONS 
The validated UPLC-MS/MS method offers several advantages 
over reported procedures, in terms of lower sample requirements, 
simplicity of extraction procedure and overall analysis time. The 
proposed method is more sensitive and rapid 
(chromatographically) compared to all other procedures for 
determination of gliclazide in biological fluids. The present 
method employs small plasma volume (50 µL) for processing, 
which is lower compared to all existing methods for gliclazide. 
With dilution integrity up to two folds, it is possible to extend the 
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upper limit of quantification to 4000 ng/mL. Matrix effect is 
assessed through post-column analyte infusion and precision 
values for calculated slopes of calibration curves. The validated 
method showed acceptable study data for the quantification of 
gliclazide in a clinical setting. Further, incurred sample reanalysis 
of 129 samples authenticates the reproducibility of the proposed 
method and is reported in any previous method.  
 
REFERENCES 
1. J.F. Yale, Oral antihyperglycemic agents and renal disease: 
new agents, new concepts, J. Am. Soc.  Nephrol. 16 (2005) 
S7-S10. 
2. H.E. Lebovitz, Oral antidiabetic agents, Med. Clin. North Am. 
88 (2004) 847-863. 
3. A. Mooranian, R. Negrulj, N. Chen-Tan, H. S. Al-Sallami, Z. 
Fang, T. Mukkur, M. Mikov, S. Golocorbin-Kon, M. 
Fakhoury, F. Arfuso, H. Al-Salami, Novel artificial cell 
microencapsulation of a complex gliclazide-deoxycholic bile 
acid formulation: a characterization study, Drug Design Dev. 
Ther. 8 (2014) 1003-1012. 
4. E. Ferrannini, Insulin resistance versus insulin deficiency in 
non-insulin-dependent diabetes mellitus: problems and 
prospects, Endocr. Rev. 19 (1998) 477-490. 
5.  D.Y. Oh, J.M. Olefsk, Omega 3 fatty acids and GPR120, Cell 
Metab. 15 (2012) 564-565.  
6.  R.N. Burns, N.H. Moniri, Agonism with the omega-3 fatty 
acids alpha-linolenic acid and docosahexaenoic acid mediates 
phosphorylation of both the short and long isoforms of the 
human GPR120 receptor, Biochem. Biophys. Res. Commun. 
396 (2010) 1030-1035.  
7.  H. Al-Salami, G. Butt, I. Tucker, R. Skrbic, S. 
Golocorbin-Kon, M. Mikov, Probiotic treatment proceeded by 
a single dose of bile acid and gliclazide exert the most 
hypoglycemic effect in Type 1 diabetic rats, Med. Hypothesis 
Res. 4 (2008) 93-101. 
8. DIAMICRON® MR (gliclazide) Product Monograph, June 
2012. Servier Canada Inc. 235 Boulevard Armand Frappier, 
Laval, Quebec H7V 4A7, Canada. http://www.servier.ca/sites 
/default/files/webform/Products/EN-DIAMICRON-MR-PI.pd
f  
9. M.R. Rouini, A. Mohajer, M.H. Tahami, A simple and 
sensitive HPLC method for determination of gliclazide in 
human serum, J. Chromatogr. B, 785 (2003) 383-386. 
10. F.G.P. Mullins, Evaluation of a novel non-porous membrane 
extraction probe to determine sulphonylureas in plasma with 
analysis by LC-MS/MS, J. Sep. Sci. 24 (2001) 593-598. 
11. J.Y. Park, K.A. Kim, S.L. Kim, P.W. Park, Quantification of 
gliclazide by semi-micro high-performance liquid 
chromatography: application to a bioequivalence study of two 
formulations in healthy subjects, J. Pharm. Biomed. Anal. 35 
(2004) 943-949. 
12. C.Y. Kuo, S.M. Wu, High-performance liquid 
chromatography with electrochemical detection for analysis of 
gliclazide in plasma, J. Chromatogr. A 1088 (2005) 131-135. 
13. G. Ling, J. Sun, J. Tang, X. Xu, Y. Sun, Z. He, Liquid 
chromatography-electrospray ionization mass spectrometric 
method for determination of gliclazide in human plasma, Anal. 
Lett. 39 (2006) 1381-1391. 
14. S.M. Foroutan, A. Zarghi, A. Shafaati, A. Khoddam, 
Application of monolithic column in quantification of 
gliclazide in human plasma by liquid chromatography, J. 
Pharm. Biomed. Anal. 42 (2006) 513-516. 
15. G.P. Zhong, H.C. Bi, S. Zhou, X. Chen, M. Huang, 
Simultaneous determination of metformin and gliclazide in 
human plasma by liquid chromatography-tandem mass 
spectrometry:  application to a bioequivalence study of two 
formulations in healthy volunteers, J. Mass Spectrom. 40 
(2005) 1462-1471.   
16. X. Hu, Y. Zheng, J. Sun, L. Shang, G. Wang, H. Zhang, 
Simultaneous quantification of benazepril, gliclazide and 
valsartan in human plasma by LC-MS-MS and application for 
rapidly measuring protein binding interaction between rhein 
and these three drugs, Chromatographia 69 (2009) 843-852. 
17. S. AbuRuz, J. Millership, J. McElnay, The development and 
validation of liquid chromatography method for the 
simultaneous determination of metformin and glipizide, 
gliclazide, glibenclamide or glimperide in plasma, J. 
Chromatogr. B 817 (2007) 277-286. 
18. K. Abro, N. Memon, M.I. Bhanger, S. Perveen, A. Panhwar, 
Comparitive study of electrospray and atmospheric pressure 
chemical ionization with liquid chromatography-mass 
spectrometry for quantitation of five antihyperglycemic agents 
utilizing monolithic column. Anal. Lett. 45 (2012) 1947-1959. 
19. P. Venkatesh, T. Harisudhan, H. Choudhary, R. Mullangi, 
N.R. Srinivas, Simultaneous estimation of six anti-diabetic 
drugs-glibenclamide, gliclazide, glipizide, pioglitazone, 
repaglinide and rosiglitazone: development of a novel HPLC 
method for use in the analysis of pharmaceutical formulations 
and its application to human plasma assay, Biomed. 
Chromatogr. 20 (2006) 1043-1048. 
20. H.H. Maurer, C. Kratzsch, T. Kraemer, F.T. Peters, A.A. 
Weber, Screening, library-assisted identification and validated 
quantification of oral antidiabetics of the sulfonylurea-type in 
plasma by atmospheric pressure chemical ionization liquid 
chromatography-mass spectrometry, J. Chromatogr. B 773 
(2002) 63-73. 
21. C. Hess, F. Musshoff, B. Madea, Simultaneous identification 
and validated quantification of 11 oral hypoglycemic drugs in 
plasma by electrospray ionization liquid 
chromatography-mass spectrometry, Anal. Bioanal. Chem. 
400 (2011) 33-41. 
22. Guidance for Industry, Bionanlytical Method Validation, US 
Department of Health and  Human Services, Food and Drug 
Administration Centre for Drug Evaluation and  Research 
(CDER), Centre for Veterinary Medicine (CVM), May 2001. 
23. B.K. Matuszewski, M.L. Constanzer, C.M. Chavez-Eng. 
Strategies for the assessment of matrix effect in quantitative 
bioanalytical methods based on HPLC-MS/MS. Anal. Chem. 
75 (2003) 3019-3030. 
24. Guidance for Industry: ICH E6 Good Clinical Practice, U.S. 
Department of Health and Human Services, Food and Drug 
Administration, Centre for Drug Evaluation and Research 
(CDER), Centre for Biologics Evaluation and Research 
(CBER), April 1996. 
25. M. Yadav, P.S Shrivastav, Incurred sample reanalysis (ISR): a 
decisive tool in bioanalytical research, Bioanalysis 3 (2011) 
1007-1024. 
 
 
 J. of Modern Drug Discovery And Drug Delivery Research           Volume 2 / Issue 1                                ISSN: 2348 –3776 9 
Citation: Pranav S. Shrivastav, et al (2014), Sensitive and Rapid Determination of Gliclazide in Human Plasma by UPLC-MS/MS 
and its Application to a Bioequivalence Study. J. of Modern Drug Discovery and Drug Delivery Research. V2I1. DOI: 
10.15297/JMDDR.V2I1.03 
 
Copyright: © 2014 Pranav S. Shrivastav. This is an open-access article distributed under the terms of the Creative Commons 
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and 
source are credited. 
 
 
 
